"A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder."
The first target FSHD, short for facioscapulohumeral muscular dystrophy may become curable as early as 2030.
The therapy does not use CRISPR CAS9 to slice the mutated genes but rather controls the epigenes that turn the genes on or off like a switch. Thus, the mutated disease causing genes can be turned off without risking slicing at the wrong place or unwanted rearrangement of the genes after having been sliced by CRISPR CAS9.
https://www.nature.com/articles/d41586-026-01976-w
No comments:
Post a Comment